Physician profile
Michael Morgan
NPI 1386716553
$10,116.45
in general payments reported to CMS, 2019-2025
42 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,324 · 2020: $360 · 2021: $1,451 · 2022: $1,881 · 2023: $1,632 · 2024: $1,221 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,068.88 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,032.22 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $1,000.80 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $984.09 | 2019-2025 | |
| Abbvie INC. | $934.63 | 2019-2025 | |
| Lilly USA, LLC | $826.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $603.34 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $601.54 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.11 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $500.41 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $354.59 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $239.22 | 2022-2024 | Rexulti |
| Allergan, INC. | $189.66 | 2019-2020 | |
| Esperion Therapeutics, INC. | $188.90 | 2021-2025 | Nexletol |
| Abbott Laboratories | $186.26 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.04 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.